Investor Alert

Market Pulse Archives

Dec. 13, 2019, 5:35 p.m. EST

Amarin gets FDA approval for new Vascepa use, U.S. shares gain in late trading

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Amarin Corp. PLC ADR (AMRN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Wallace Witkowski

Amarin Corp. /zigman2/quotes/201885540/composite AMRN +4.67% received U.S. approval to market its drug Vascepa to reduce the risk of cardiovascular events in people with high triglyceride levels, according to the Food and Drug Administration late Friday. U.S.-traded shares were halted at $24.12 at 10:06 a.m. Eastern, hours before the announcement; when they resumed trading at 5:30 p.m., they gained more than 2% in after-hours action. "Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy," the agency said in a statement. Vascepa was originally approved in 2012 to treat patients with severely high triglyceride levels. ADRs of Dublin-based Amarin are up 77% year-to-date, compared with a 26% rise in the S&P 500 index /zigman2/quotes/210599714/realtime SPX +1.60%

Read the full story:
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

US : U.S.: Nasdaq
$ 3.81
+0.17 +4.67%
Volume: 7.38M
Sept. 25, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.47 billion
Rev. per Employee
+51.87 +1.60%
Volume: 0.00
Sept. 25, 2020 5:06p

Get news alerts on Amarin Corp. PLC ADR — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.